Appili Therapeutics Inc (APLIF)
Appili Therapeutics Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in Halifax, NS, CA. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $1.2M. On trailing twelve-month figures it carries a trailing P/E of -0.28, a net margin of -1236.1%. Its beta of -0.21 implies it has historically moved less than the broad market.
Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. It focuses on building and advancing a diverse portfolio of anti-infective programs such as ATI-1501, ATI-1503, and ATI-1701. The company was founded on May 7, 2015 and is headquartered in Halifax, Canada.
Appili Therapeutics Inc is most often compared with the following Healthcare names: